|
[1]
|
D'Haens GR, Panaccione R, Higgins PD, et al. The London Position Statement of the World Congress of Gastroenterology on Biological Therapy for IBD with the European Crohn's and Colitis Organization:when to start, when to stop, which drug to choose, and how to predict response?[J]. Am J Gastroenterol, 2011, 106:199-212. doi: 10.1038/ajg.2010.392 |
|
[2]
|
Ben-Horin S, Kopylov U, Chowers Y. Optimizing anti-TNF treatments in inflammatory bowel disease[J]. Autoimmun Rev, 2014, 13:24-30. doi: 10.1016/j.autrev.2013.06.002 |
|
[3]
|
Gisbert JP, Panes J. Loss of response and requirement of infliximab dose intensification in Crohn's disease:a review[J]. Am J Gastroenterol, 2009, 104:760-767. http://europepmc.org/abstract/MED/19174781 |
|
[4]
|
Rostholder E, Ahmed A, Cheifetz AS, et al. Outcomes after escalation of infliximab therapy in ambulatory patients with moderately active ulcerative colitis[J]. Aliment Pharmacol Ther, 2012, 35:562-567. doi: 10.1111/j.1365-2036.2011.04986.x |
|
[5]
|
Yamada S, Yoshino T, Matsuura M, et al. Long-term efficacy of infliximab for refractory ulcerative colitis:results from a single center experience[J]. BMC Gastroenterol, 2014, 23:1471-1480. http://www.biomedcentral.com/1471-230X/14/80 |
|
[6]
|
Baert F, Drobne D, Gils A, et al. Early trough levels and antibodies to infliximab predict safety and success of reinitiation of infliximab therapy[J]. Clin Gastroenterol Hepatol, 2014, 12:1474-1481. doi: 10.1016/j.cgh.2014.01.033 |
|
[7]
|
Zampeli E, Gizis M, Siakavellas SI, et al.Predictors of response to anti-tumor necrosis factor therapy in ulcerative colitis[J]. World J Gastrointest Pathophysiol, 2014, 5:293-303. doi: 10.4291/wjgp.v5.i3.293 |
|
[8]
|
Steenholdt C, Palarasah Y, Bendtzen K, et al. Pre-existing IgG antibodies cross-reacting with the Fab region of infliximab predict efficacy and safety of infliximab therapy in inflammatory bowel disease[J]. Aliment Pharmacol Ther, 2013, 37:1172-1183. doi: 10.1111/apt.12330 |
|
[9]
|
Sprakes MB, Ford AC, Warren L, et al. Efficacy, tolerability, and predictors of response to infliximab therapy for Crohn's disease:a large single centre experience[J]. J Crohns Colitis, 2012, 6:143-153. doi: 10.1016/j.crohns.2011.07.011 |
|
[10]
|
De Vos M, Louis EJ, Jahnsen J, et al. Consecutive fecal calprotectin measurements to predict relapse in patients with ulcerative colitis receiving infliximab maintenance therapy[J]. Inflamm Bowel Dis, 2013, 19:2111-2117. doi: 10.1097/MIB.0b013e31829b2a37 |
|
[11]
|
Laharie D, Mesli S, El Hajbi F, et al. Prediction of Crohn's disease relapse with faecal calprotectin in infliximab responders:a prospective study[J]. Aliment Pharmacol Ther, 2011, 34:462-469. doi: 10.1111/j.1365-2036.2011.04743.x |
|
[12]
|
Molander P, Färkkilä M, Ristimäki A, et al. Does fecal calprotectin predict short-term relapse after stopping TNFα-blocking agents in inflammatory bowel disease patients in deep remission?[J]. J Crohns Colitis, 2014, 46:1873-1899. http://ecco-jcc.oxfordjournals.org/content/9/1/33 |
|
[13]
|
Seow CH, Newman A, Irwin SP, et al. Trough serum infliximab:a predictive factor of clinical outcome for infliximab treatment in acute ulcerative colitis[J]. Gut, 2010, 59:49-54. doi: 10.1136/gut.2009.183095 |
|
[14]
|
Cornillie F, Hanauer SB, Diamond RH, et al. Postinduction serum infliximab trough level and decrease of C-reactive protein level are associated with durable sustained response to infliximab:a retrospective analysis of the ACCENT I trial[J]. Gut, 2014, 63:1721-1727. doi: 10.1136/gutjnl-2012-304094 |
|
[15]
|
Adedokun OJ, Sandborn WJ, Feagan BG, et al. Association between serum concentration of infliximab and efficacy in adult patients with ulcerative colitis[J]. Gstroenterology, 2014, 147:1296-1307.. doi: 10.1053/j.gastro.2014.08.035 |
|
[16]
|
Baert F, Noman M, Vermeire S, et al.Influence of immunogenicity on the long-time efficacy of infliximab in Crohn's disease[J].N Engl J Med, 2003, 348:601-608. doi: 10.1056/NEJMoa020888 |
|
[17]
|
Nanda KS, Cheifetz AS, Moss AC. Impact of antibodies to infliximab on clinical outcomes and serum infliximab levels in patients with inflammatory bowel disease (IBD):a meta-analysis[J].Am J Gastroenterol, 2013, 108:40-47. doi: 10.1038/ajg.2012.363 |
|
[18]
|
Vande Casteele N, Gils A, Singh S, et al. Antibody response to infliximab and its impact on pharmacokinetics can be transient[J]. Am J Gastroenterol, 2013, 108:962-971. doi: 10.1038/ajg.2013.12 |
|
[19]
|
Vande Casteele N, Feagan BG, Gils A, et al. Therapeutic drug monitoring in inflammatory bowel disease:current state and future perspectives[J].Curr Gastroenterol Rep, 2014, 16:378. doi: 10.1007/s11894-014-0378-0 |
|
[20]
|
Guerra I, Chaparro M, Bermejo F, et al. Utility of measuring serum concentrations of anti-TNF agents and anti-drug antibodies in inflammatory bowel disease[J]. Curr Drug Metab, 2011, 12:594-598. doi: 10.2174/138920011795713689 |
|
[21]
|
Eser A, Primas C, Reinisch W. Drug monitoring of biologics in inflammatory bowel disease[J]. Curr Opin Gastroenterol, 2013, 29:391-396. doi: 10.1097/MOG.0b013e328361f7f6 |
|
[22]
|
Farrell RJ, Alsahli M, Jeen YT, et al. Intravenous hydrocortisone premedication reduces antibodies to infliximab in Crohn's disease:a randomized controlled trial[J].Gastroenterology, 2003, 124:917-924. doi: 10.1053/gast.2003.50145 |
|
[23]
|
Mantzaris GJ, Viazis N, Petraki K, et al. A pilot study comparing hydrocortisone premedication to concomitant azathioprine treatment in preventing loss of response to infliximab[J]. Eur J Gastroenterol Hepatol, 2009, 21:1042-1048. doi: 10.1097/MEG.0b013e32832937e3 |
|
[24]
|
Colombel JF, Sandborn WJ, Reinisch W, et al. Infliximab, azathioprine, or combination therapy for Crohn's disease[J]. N Engl J Med, 2010, 362:1383-1395. doi: 10.1056/NEJMoa0904492 |
|
[25]
|
Deepak P, Stobaugh DJ, Ehrenpreis ED. Infectious complications of TNF-alpha inhibitor monotherapy versus combination therapy with immunomodulators in inflammatory bowel disease:analysis of the Food and Drug Administration Adverse Event Reporting System[J]. J Gastrointestin Liver Dis, 2013, 22:269-276. http://europepmc.org/abstract/med/24078983 |
|
[26]
|
Feagan BG, McDonald JW, Panaccione R, et al. Methotrexate in combination with infliximab is no more effective than infliximab alone in patients with Crohn's disease[J]. Gastroenterology, 2014, 146:681-688. doi: 10.1053/j.gastro.2013.11.024 |
|
[27]
|
Kopylov U, Mantzaris GJ, Katsanos KH, et al. The efficacy of shortening the dosing interval to once every six weeks in Crohn's patients losing response to maintenance dose of inflixi-mab[J]. Aliment Pharmacol Ther, 2011, 33:349-357. doi: 10.1111/j.1365-2036.2010.04523.x |
|
[28]
|
Cesarini M, Katsanos K, Papamichael K, et al. Dose optimization is effective in ulcerative colitis patients losing response to infliximab:a collaborative multicentre retrospective study[J]. Dig Liver Dis, 2014, 46:135-139. doi: 10.1016/j.dld.2013.10.007 |
|
[29]
|
Taxonera C, Olivares D, Mendoza JL, et al.Need for infliximab dose intensification in Crohn's disease and ulcerative colitis[J]. World J Gastroenterol, 2014, 20:9170-9177. http://www.cnki.com.cn/Article/CJFDTotal-ZXXY201427042.htm |
|
[30]
|
Steenholdt C, Brynskov J, Thomsen OO, et al. Individualised therapy is more cost-effective than dose intensification in patients with Crohn's disease who lose response to anti-TNF treatment:a randomised, controlled trial[J]. Gut, 2014, 63:919-927. doi: 10.1136/gutjnl-2013-305279 |
|
[31]
|
Song YN, Zheng P, Xiao JH, et al. Efficacy and safety of adalimumab for the Crohn's disease:a systematic review and meta-analysis of published randomized placebo-controlled trials[J]. Eur J Clin Pharmacol, 2014, 70:907-914. doi: 10.1007/s00228-014-1702-1 |
|
[32]
|
Kaplan GG, Hur C, Korzenik J, et al. Infliximab dose escalation vs initiation of adalimumab for loss of response in Crohn's disease:a cost-effectiveness analysis[J]. Aliment Pharmacol Ther, 2007, 26:1509-1520. doi: 10.1111/j.1365-2036.2007.03548.x |
|
[33]
|
Baert F, Vande Casteele N, Tops S, et al. Prior response to infliximab and early serum drug concentrations predict effects of adalimumab in ulcerative colitis[J]. Aliment Pharmacol Ther, 2014, 40:1324-1332. doi: 10.1111/apt.12968 |
|
[34]
|
Sandborn WJ, Abreu MT, D'Haens C, et al. Certolizumab pegol in patients with moderate to severe Crohn's disease and secondary failure to infliximab[J]. Clin Gastroenterol Hepatol, 2010, 8:688-695. doi: 10.1016/j.cgh.2010.04.021 |
|
[35]
|
Sandborn WJ, Feagan BG, Marano C, et al. Subcutaneous golimumab induces clinical response and remission in patients with moderate-to-severe ulcerative colitis[J]. Gastroentero-logy, 2014, 146:85-95. doi: 10.1053/j.gastro.2013.05.048 |
|
[36]
|
Danese S, Panés J. Development of drugs to target interactions between leukocytes and endothelial cells and treatment algorithms for inflammatory bowel diseases[J]. Gastroente-rology, 2014, 147:981-989. doi: 10.1053/j.gastro.2014.08.044 |
|
[37]
|
Sandborn WJ, Gasink C, Gao LL, et al. Ustekinumab induction and maintenance therapy in refractory Crohn's disease[J]. N Engl J Med, 2012, 367:1519-1528. doi: 10.1056/NEJMoa1203572 |
|
[38]
|
Dignass A, Lindsay JO, Sturm A, et al. Second European evidence based consensus on the diagnosis and management of ulcerative colitis part 2:current management[J]. J Crohns Colitis, 2012, 6:991-1030. doi: 10.1016/j.crohns.2012.09.002 |
|
[39]
|
Abreu MT, von Tirpitz C, Hardi R, et al. Extracorporeal photopheresis for the treatment of refractory Crohn's disease:results of an open-label pilot study[J]. Inflamm Bowel Dis, 2009, 15:829-836. doi: 10.1002/ibd.20833 |
|
[40]
|
Martínez-Montiel Mdel P, Gómez-Gómez GJ, Flores AI. Therapy with stem cells in inflammatory bowel disease[J]. World J Gastroenterol, 2014, 20:1211-1227. doi: 10.3748/wjg.v20.i5.1211 |
作者投稿
专家审稿
编辑办公
邮件订阅
RSS
点击查看大图
下载:
